Carvedilol is a beta-blocker with alpha-1 and beta-1+beta-2 blocking activity, indicated for hypertension and heart failure. The alpha-1 blockade provides additional vasodilation.
Also known as: Coreg
Beta-blocker + CYP2D6 inhibitor: fluoxetine may increase carvedilol levels.
Carvedilol is metabolised by CYP2D6. Fluoxetine inhibits CYP2D6, increasing levels.
Heart rate, blood pressure, signs of bradycardia.
Symptomatic bradycardia.
Monitor heart rate and blood pressure. Reduce dose if necessary.
DailyMed/FDA; EMC-EMC PT
Food significantly increases carvedilol absorption (should be taken with food).
Always take with food to ensure consistent absorption.
DailyMed/FDA (NIH/NLM) — approved Carvedilol (Coreg) label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07c619c6-4a0c-445e-94fa-664a54f68a39
CONTRAINDICATED in decompensated HF.
Stabilise first.
DailyMed/FDA; EMC-EMC PT
No documented pregnancy or breastfeeding information.
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Non-selective beta-blocker (β1+β2) with alpha-1 adrenergic blocking activity. Alpha-1 blockade provides vasodilation and reduces peripheral vascular resistance.
Simultaneously blocks beta-1, beta-2, and alpha-1 receptors, reducing heart rate, contractility, and peripheral vascular resistance. Triple antihypertensive effect.
Oral bioavailability: 25-35%. Food significantly increases absorption (should be taken with food). Tmax: 1-2 hours.
Metabolised by CYP2D6 and CYP2C9. Inhibited by fluoxetine, paroxetine. CYP2D6 polymorphism affects exposure.
6-10 hours. Elimination: ~60% faeces, ~16% urine. Extensive hepatic metabolism.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
